As of 2024-12-12, the Intrinsic Value of ExpreS2ion Biotech Holding AB (EXPRS2.ST) is (3,234.05) SEK. This EXPRS2.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 23.90 SEK, the upside of ExpreS2ion Biotech Holding AB is -13,631.60%.
The range of the Intrinsic Value is (36,526.03) - (1,724.37) SEK
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (36,526.03) - (1,724.37) | (3,234.05) | -13631.6% |
| DCF (Growth 10y) | (2,582.36) - (54,337.04) | (4,836.40) | -20336.0% |
| DCF (EBITDA 5y) | (2,125.38) - (3,155.38) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (3,096.45) - (5,143.41) | (1,234.50) | -123450.0% |
| Fair Value | -108.01 - -108.01 | -108.01 | -551.93% |
| P/E | (684.36) - (669.67) | (689.12) | -2983.3% |
| EV/EBITDA | (772.50) - (1,045.16) | (905.03) | -3886.7% |
| EPV | (437.22) - (764.36) | (600.79) | -2613.8% |
| DDM - Stable | (385.05) - (9,915.85) | (5,150.46) | -21650.0% |
| DDM - Multi | (1,945.99) - (39,067.25) | (3,711.51) | -15629.4% |
| Market Cap (mil) | 50.20 |
| Beta | 2.20 |
| Outstanding shares (mil) | 2.10 |
| Enterprise Value (mil) | -17.99 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.95% |
| Cost of Debt | 30.95% |
| WACC | 6.77% |